Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS)

X Baraliakos; Mikkel Østergaard; L. S. Gensler; D. Poddubnyy; E. Y. Lee; U Kiltz; R. Martin; H. Sawata; A. Readie; B Porter

doi:10.1111/1756-185X.13361

Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS)

X Baraliakos, Mikkel Østergaard, L. S. Gensler , D. Poddubnyy, E. Y. Lee, U Kiltz, R. Martin, H. Sawata, A. Readie, B Porter

Department of Clinical Medicine

Original language	English
Article number	SU147
Journal	International Journal of Rheumatic Diseases
Volume	21
Issue number	S1
Pages (from-to)	121-122
ISSN	1756-1841
DOIs	https://doi.org/10.1111/1756-185X.13361
Publication status	Published - 2018

Access to Document

10.1111/1756-185X.13361

Cite this

Baraliakos, X., Østergaard, M., Gensler , L. S., Poddubnyy, D., Lee, E. Y., Kiltz, U., Martin, R., Sawata, H., Readie, A., & Porter, B. (2018). Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS). International Journal of Rheumatic Diseases, 21(S1), 121-122. Article SU147. https://doi.org/10.1111/1756-185X.13361

Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS). / Baraliakos, X; Østergaard, Mikkel; Gensler , L. S. et al.
In: International Journal of Rheumatic Diseases, Vol. 21, No. S1, SU147, 2018, p. 121-122.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Baraliakos, X, Østergaard, M, Gensler , LS, Poddubnyy, D, Lee, EY, Kiltz, U, Martin, R, Sawata, H, Readie, A & Porter, B 2018, 'Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS)', International Journal of Rheumatic Diseases, vol. 21, no. S1, SU147, pp. 121-122. https://doi.org/10.1111/1756-185X.13361

@article{c57a3b7ff6234987ac9ace23a459b38e,

title = "Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS)",

author = "X Baraliakos and Mikkel {\O}stergaard and Gensler, {L. S.} and D. Poddubnyy and Lee, {E. Y.} and U Kiltz and R. Martin and H. Sawata and A. Readie and B Porter",

year = "2018",

doi = "10.1111/1756-185X.13361",

language = "English",

volume = "21",

pages = "121--122",

journal = "International Journal of Rheumatic Diseases",

issn = "1756-1841",

publisher = "Wiley-Blackwell Publishing Asia",

number = "S1",

}

TY - ABST

T1 - Comparison of secukinumab and adalimumab biosimilar on radiographic progression in ankylosing spondylitis patients: Design of a randomized, phase‐IIIb study (SURPASS)

AU - Baraliakos, X

AU - Østergaard, Mikkel

AU - Gensler , L. S.

AU - Poddubnyy, D.

AU - Lee, E. Y.

AU - Kiltz, U

AU - Martin, R.

AU - Sawata, H.

AU - Readie, A.

AU - Porter, B

PY - 2018

Y1 - 2018

U2 - 10.1111/1756-185X.13361

DO - 10.1111/1756-185X.13361

M3 - Conference abstract in journal

SN - 1756-1841

VL - 21

SP - 121

EP - 122

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

IS - S1

M1 - SU147

ER -